Weight-loss drugs could stop hormone replacement therapy from working and increase the associated risks, guidance has warned.

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

A Weight Loss Illusion with Dangers Ahead** In an age where the quest for quick fixes dominates our society, the emergence of Ozempic as the ...

Ozempic and Munjaro: how do weight-loss drugs work and what are the side effects? - Ozempic and similar jabs promise weight ...

Doctors have said there is a risk that weight loss jabs such as Ozempic and Mounjaro could raise the risk of being diagnosed ...

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link ...

In this Asking Eric, readers get heartfelt advice on why feeding wildlife is risky, how to handle friends’ weight loss ...

Dear Eric: I wanted to add a perspective to “Sad Aunt,” who felt great resentment at the nephews who were “gatekeepers” when ...